The real story for CYTK right now is the cardiac product for CHF. Their kinesin product used in these oncology studies has had only modest results at best in prior clinical studies. The cardiac product will define the future for CYTK for good or bad.
That being said I too was surprised to see the stock up NOT down and I quess the market is smarter then I expected, at least in this case.
I am invested in CYTK as I think their cardiac product that affects caridac contractility w/o being an inotrope and w/o increasing myocardial oxygen consumption may be a blockbuster.